Posted by AGORACOM
at 4:26 PM on Tuesday, July 27th, 2021
Xali Gold ( XGC:TSXV ) has assembled a Western Mexico project portfolio of gold assets and have developed a strategy for organic growth to exploit its Flagship Gold Project El Oro, a prolific high-grade gold-silver epithermal vein system.
Xali has acquired gold and silver projects with near surface exploration potential & near-term production potential:
El Dorado Gold-Silver Project:
Rights to the El Dorado gold and silver historic mines was the initial step in this strategy, providing Xali the right to explore and produce gold, silver and other metals for life of mine.
Cocula Gold Project: profit-sharing agreement
Near term, low cost production potential by leaching and/or flotation
Retain 70% of profits
Recent drill targets Identified
Acquisition of the “SDA” Plant:
The SDA Mill is a fully operational flotation plant which also includes a precious metals leach circuit – Merrill Crowe system and associated assets, licenses and agreements, suitable for treating high grade gold and silver mineralization.
These assets are being positioned to create cash flow to develop Flagship El Oro Gold District where the primary focus is the past producing San Rafael Vein; 2.4km strike of high-grade Epithermal veins.
The project covers 20 veins with past production and more than 57 veins in total and approximately 6.4 million ounces of gold and 74 million ounces of silver were reported to have been produced from just two of these veins. Historical Average grades: 10-12 g/t gold & 120-160 g/t silver
Xali has identified 31 exploration targets
Flooding in one section of the San Rafael vein in 1929 resulted in the other two sections flooding and work ceasing abruptly and unexpectedly. El Oro was not mined out. The financial benefits from Western Mexico operations will translate across platforms to strengthen the Company’s efforts to explore and potentially mine areas demonstrated to contain mineralization of value
Chief Medical Officer Dr. Reid Robison explains the three pillars of Ketamine therapy and the steps we take to prevent misuse.
“I’ve never had a client who we’ve done the appropriate process with who has entered into a troubled relationship with ketamine through the course of their treatment.”
Our Chief Medical Officer joins Health Professional Radio to discuss psychedelic medicine and our rapid expansion phase as we grow our network of clinics, research sites and therapeutic retreats specialized in psychedelic medicine.
“We’re expanding even more with the need that has come up through the pandemic and the willingness to look towards new and improved ways of approaching our mental health”
We are pleased to announce that we have submitted our application to have our common shares posted for trading on the OTCQB® Venture Market, a U.S. trading platform operated by the OTC Markets Group, Inc.
“Having the Company’s common shares posted for trading on the OTCQB and providing a more efficient way of trading our shares will be an important milestone in our strategy of building awareness and enhancing accessibility amongst United States investors looking for exposure to the growth potential of Novamind’s mental health and psychedelic medicine business,” said Yaron Conforti, CEO and Director of Novamind.
A groundbreaking Yale study has uncovered a new dimension in understanding how psychedelics affect us: with small, physical changes to the brain. The study tracked how psilocybin, the active molecule in psychedelic mushrooms, not only has significant and long-lasting effects on mood but actually stimulates growth of new neuronal connections within the brain.
Governments around the world accelerated the clinical research process to develop vaccines for the Covid-19 health crisis. So why can’t we do the same for drugs to treat the mental health crisis? Monnica Williams and Morgan Campbell argue the point in the Baltimore Sun, comparing the investment in mental health treatment with physical health treatment: Investment in psychiatric therapies has remained very low compared to the burden of diseases, with $1.80 per $1,000 in disease burden for major depression and $0.40 for bipolar disorder compared to $9.40 for COPD, $7.60 for diabetes and $75.50 for cancer.
The popularity of using ketamine as a psychedelic treatment is only growing, according to ABC News. Less than 60 ketamine clinics existed in the United States in 2015. In 2018, that number climbed to over 300. With over 7,000 ketamine treatments to date, Novamind remains one of the busiest and most experienced ketamine practices in America.
Michael Pollan, the award-winning journalist who wrote “How to Change Your Mind,” a comprehensive examination of psychedelics history and his personal experience, is back. His new book contrasts the effects of three plant-based substances: caffeine, opium and mescaline. His section on mescaline further destigmatizes psychedelics through a critical and journalistic lens.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Reid Robison, Dr. Steve Thayer, and Derick Moody, PA-C discuss whether or not the mystical experience caused by many psychedelic medicines is a necessary factor for the healing they promote.
Microdose covers ketamine’s history as an off-label treatment for depression, the FDA approval of Spravatoᵀᴹ (esketamine) and what the future looks like for these drugs. CEO Yaron Conforti and CMO Dr. Reid Robison were both interviewed for the article.
“Cost and accessibility are universal challenges we face in our healthcare system, and these will also apply to psilocybin, MDMA, and nearly every drug that comes to market, at least during the initial years of patent exclusivity,” said Robison.
We are pleased to announce that our wholly owned subsidiary, Cedar Clinical Research has been selected as a research site for a study titled “A phase IIb, randomized, double blind, two arm study to investigate the effects of BNC210 tablet formulation compared to placebo in adults with post-traumatic stress disorder”.
“This clinical trial leverages CCR’s established track record studying novel treatments for PTSD and other difficult to treat mental health conditions.” said Dr. Reid Robison, Chief Medical Officer of Novamind.
Larger and stronger neural connections. According to new research out of Yale, it’s all about the increased density of dendritic spines. “Small protrusions found on nerve cells which aid in the transmission of information between neurons. Chronic stress and depression are known to reduce the number of these neuronal connections.” If psilocybin can create larger and stronger neural connections, the potential for treating depression and creating lasting change improves significantly.
While “there have been no research studies in humans showing that LSD can treat allergies of any kind” one patent application hopes that one day LSD will be able to treat food allergies. The article references a story about a claim (not research- or evidence-based) that LSD cured a lifelong cat allergy and goes into more detail about the patent process and what might stand in the way of this one getting approved. “It’s based on luck.” And it’s another entrant to the race to patent psychedelics.
Posted by AGORACOM-JC
at 4:54 PM on Friday, July 16th, 2021
Kiaro Holdings is an multi-channel cannabis retailer and distributor with existing storefronts across British Columbia , Saskatchewan and Ontario, a wholesale distribution servicing Saskatchewan and ecommerce sites in Canada , the US and Australia, which have resulted in the following:
If you believe in the long-term future of the cannabis market, then you have to discover KIARO by watching our first ever interview with CEO Daniel Petrov.
Posted by AGORACOM-JC
at 4:10 PM on Friday, July 16th, 2021
FOBI AI is a global leader in providing real-time data analytics through artificial intelligence to drive customer activation and engagement for enterprise level retailers.
More than just lip service, these are just a sample of the major milestones reached by $FOBI over the past 9 months:
Strategic Alliance with global data leader – NeilsonIQ – to “Transform Retail Sector”
A partnership with NTT DATA, a top-ranked global IoT services company, and subsidiary of Nippon Telegraph and Telephone, the world’s 4th largest telecom company, ranked 55th In Fortune Global 500.
Approved for Oracle Partner Network
Pilot Projects with Sobeys, TELUS, Certas and other national level retailers
Multi-Year Direct Seller Agreement With TELUS, in which TELUS resells FOBI solutions to national business customers
Posted by AGORACOM
at 4:35 PM on Thursday, July 15th, 2021
Fabled Silver Gold (FCO TSXV) ( FBSGF: OTC ) controls 100% of the Santa Maria mine gold and silver property in Mexico. It is a high grade silver gold property that is situated right in the middle of the Mexican Epithermal silver gold belt that has reportedly produced more silver than any other equivalent area in the entire planet.
To say it’s a mining friendly jurisdiction is an understatement.
Multiple major operators are in the vicinity and it’s already got a silver equivalent 43-101 of 3.2m ounces, but is looking to add to that significantly with recent intercepts of 2269 g/t silver.
That is not a typo, in other words it is also 2.269 kilos AgEq or 72 troy ounce.
Just recently, Fabled encountered a new, previously unknown gold zone with the discovery of a new high grade gold system with values up 10.85 g/t Au within 30.7m grading 161.09 Ag Eq
This quote from Peter J. Hawley, CEO and President sums up the future potential aptly:
……“ we have found a new, never discovered high grade gold mineral domain system, with silver credits, over consistent widths in an area never explored, and which remains open to the west and at depth, plunging 45 degrees to the west and open in all directions for expansion.
Recent underground diamond drilling also intercepted 4 Zones of Silver Mineralization including 314.35 g/t Ag Eq over 0.80m.
Fabled is intent on proving Santa Maria is bigger and of potentially higher grade than the market understands and is well on its way with intercepts such as these.
Sit back with your favorite beverage as Peter Hawley explains the importance of the latest discovery within the context of the Fabled corporate presentation
The Santa Maria Project is poised to deliver as exploration continues to deliver discoveries through both above and underground drill programs.
Posted by AGORACOM-JC
at 5:47 PM on Tuesday, July 13th, 2021
PyroGenesis is the world leader in the development of advanced plasma processes and products. In short, their plasma torch technology has been the foundation of multiple successful applications around the world that significantly reduce both greenhouse gases and costs of doing business for some of the world’s biggest companies in these following verticals:
Ultra High-Tech 3D Printing (Additive Manufacturing)
Iron Ore Pelletization
Aluminum Smelters Recovery Of Dross
High-Purity Silicon For EV Batteries
….. More
Today, PyroGenesis CEO Peter Pascali provides investors with a comprehensive update of each vertical and some of the major business developments taking place within each of them. Watch our great interview with CEO Peter Pascali
Posted by AGORACOM-JC
at 4:06 PM on Monday, July 12th, 2021
As the name implies “PropTech” is a combination of two words and stands for “property technology.” As simple as that is, the implementation and importance of PropTech is anything but, which is why many companies are trying to capitalize on the rapidly growing paradigm shift, while Universal PropTech (UPI:TSXV) is actually delivering healthy building solutions developers, owners and operators across Canada.
This is comprised of awarded and not executed work, made up of a combination of service contracts and project work in both HVAC Building Automation and Mechanical lines of business.
We sat down with Frank Carnevale, CGO of Universal Proptech, to talk about their multimillion-dollar backlog. Check out the full interview below.
Posted by AGORACOM
at 2:26 PM on Saturday, July 10th, 2021
If there is one thing we know about governments – whether it’s at the local, state, or federal level – it is that they can be hugely inefficient.
HealthSpace Data Systems’ (CSE: HS) (OTCQB: HDSLF) (Frankfurt: 38H) “empowering government efficiency” solution has led the firm to become an industry leading tech pioneer, providing both enterprise- and mobile internet-based applications to more than 500 state and local government organizations in North America, including in California, Missouri, Illinois, Wisconsin and Ontario.
In April, HealthSpace launched GovCall, a teleconferencing platform focused exclusively on the government market. The company now offers the only integrated product suite that incorporates inspection, administration and analytics across all platforms in North America.
cloud-based and mobile platform helps revolutionize every aspect of government regulatory work
including licensing and inspections, accounting, even disease surveillance
The company continues to go from strength to strength. Last month, CEO Silas Garrison presented a sizable corporate update, outlining:
a strong start to the year: US$3.8M in new deals in Q1 2021 and US$5.6M in deals since the year’s start
Anticipate achieving US$8M in ARR under contract within the next 6-9 months.
This past December $HS raised more than CAD$6M million in equity.
Will be used to deal with more aggressive R&D and feature development strategies, as well as handle the increasing volume of customers
$HS has doubled the number of team members over the last 9 months, with over 30 new hires, and has 74 full-time team members today
Paul Victor joined as our Head of Engineering in March
Chirag Bhatt joined the team in May as Director of Regulatory Affairs for Environmental Health.
The total pipeline of deals stands at over US$22M, expected to close over the next 12-18 months.
Since last corporate update in Nov 2020, $HS has converted approximately US$7.3m of the pipeline to either signed or contract awards.
Annualized, this is an 80% conversion rate from the pipeline (contract numbers, not by dollars). As of today, the pipeline represents the addition of US$6.8M in new deals added to the pipeline in 2021.
The deals in this pipeline are of all sizes, ranging from US$9,000 to over US$5m.
We sat down with him to talk through the company’s progress and look ahead to 2022 and beyond.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Reid Robison, Dr. Steve Thayer, and Derick Moody, PA-C discuss whether or not the mystical experience caused by many psychedelic medicines is a necessary factor for the healing they promote.
Microdose covers ketamine’s history as an off-label treatment for depression, the FDA approval of Spravatoᵀᴹ (esketamine) and what the future looks like for these drugs. CEO Yaron Conforti and CMO Dr. Reid Robison were both interviewed for the article.
“Cost and accessibility are universal challenges we face in our healthcare system, and these will also apply to psilocybin, MDMA, and nearly every drug that comes to market, at least during the initial years of patent exclusivity,” said Robison.
We are pleased to announce that our wholly owned subsidiary, Cedar Clinical Research has been selected as a research site for a study titled “A phase IIb, randomized, double blind, two arm study to investigate the effects of BNC210 tablet formulation compared to placebo in adults with post-traumatic stress disorder”.
“This clinical trial leverages CCR’s established track record studying novel treatments for PTSD and other difficult to treat mental health conditions.” said Dr. Reid Robison, Chief Medical Officer of Novamind.
Larger and stronger neural connections. According to new research out of Yale, it’s all about the increased density of dendritic spines. “Small protrusions found on nerve cells which aid in the transmission of information between neurons. Chronic stress and depression are known to reduce the number of these neuronal connections.” If psilocybin can create larger and stronger neural connections, the potential for treating depression and creating lasting change improves significantly.
While “there have been no research studies in humans showing that LSD can treat allergies of any kind” one patent application hopes that one day LSD will be able to treat food allergies. The article references a story about a claim (not research- or evidence-based) that LSD cured a lifelong cat allergy and goes into more detail about the patent process and what might stand in the way of this one getting approved. “It’s based on luck.” And it’s another entrant to the race to patent psychedelics.
